

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 November 2023 (09.11.2023)



(10) International Publication Number
WO 2023/215769 A1

(51) International Patent Classification:
C07K 16/24 (2006.01) A61P 17/04 (2006.01)
A61P 17/00 (2006.01)

(21) International Application Number:
PCT/US2023/066527

(22) International Filing Date:
03 May 2023 (03.05.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/338,588 05 May 2022 (05.05.2022) US

(71) Applicant: DERMIRA, INC. [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventor: LIMA, Renata Gontijo; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: GAO, Xiaoguang et al.; ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: IL-13 ANTIBODIES FOR THE TREATMENT OF ATOPIC DERMATITIS




Figure 1

(57) Abstract: Provided herein are methods, uses and pharmaceutical compositions of anti-IL-13 antibodies, such as lebrizumab, for treating atopic dermatitis in pediatric patients. Also provided herein are doses and dosing regimens for the methods and uses of anti-IL-13 antibodies, such as lebrizumab, for treating atopic dermatitis in pediatric patients.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*